New data for daclizumab in MS


Daclizumab is an IgG1 anti-CD25 monoclonal antibody that blocks IL-2-mediated lymphocyte activation. The drug (Zenapax) was originally used to prevent tissue rejection but was withdrawn by Roche in 2009 due to declining demand.     

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page